{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T04:04:08Z","timestamp":1780027448978,"version":"3.53.1"},"reference-count":153,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001631","name":"University College Dublin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001631","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>Opinion Statement<\/jats:title>\n                  <jats:p>As survival among reproductive-age patients with breast cancer continues to improve with modern therapies, concerns regarding fertility preservation, gonadotoxicity, and pregnancy safety have become increasingly prominent. Fertility considerations are well-recognized contributors to treatment refusal and premature discontinuation, therefore, oncofertility counselling should be initiated at diagnosis and integrated into therapeutic planning. Prompt referral for fertility preservation is essential for patients who may wish to conceive, without compromising oncologic outcomes. Systemic therapy selection should remain driven by tumour biology and recurrence risk; however, when clinically equivalent regimens are available, those with lower gonadotoxic potential are preferred. Cytotoxic chemotherapy is the main determinant of permanent ovarian insufficiency, and temporary ovarian suppression during chemotherapy should be routinely considered in appropriate candidates. Endocrine therapy is not associated with irreversible ovarian damage, but its long duration necessitates individualized planning for pregnancy, including supervised treatment interruption in selected low-risk patients. HER2-monoclonal antibodies should be delivered according to standard indications, as it does not appear to confer substantial additional ovarian toxicity beyond chemotherapy; however, pregnancy must be avoided during treatment. For antibody\u2013drug conjugates, PARP inhibitors, and CDK 4 and 6 inhibitors, the absence of prospective human fertility data supports a precautionary approach, including pre-treatment fertility preservation, effective contraception during therapy, and adherence to recommended washout periods. Given the substantial gaps in clinical evidence, transparent communication of uncertainty is essential. The integration of standardized reproductive endpoints into clinical trials, alongside the development of predictive tools is critical to support evidence-based counselling and optimize long-term survivorship outcomes.<\/jats:p>","DOI":"10.1007\/s11864-026-01396-y","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T03:43:47Z","timestamp":1780026227000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4\/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer"],"prefix":"10.1007","volume":"27","author":[{"given":"Karolina","family":"Weiner-Gorzel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda","family":"McSorley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice M.","family":"Walshe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"1396_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/S12609-023-00516-Z","volume":"16","author":"KH Natsuhara","year":"2024","unstructured":"Natsuhara KH, Chien AJ. Impact of systemic therapy on fertility in women with early-stage breast cancer. Curr Breast Cancer Rep. 2024;16:61\u20138. https:\/\/doi.org\/10.1007\/S12609-023-00516-Z.","journal-title":"Curr Breast Cancer Rep"},{"key":"1396_CR2","doi-asserted-by":"publisher","DOI":"10.7150\/JCA.64205","volume":"12","author":"MJ Bou-Dargham","year":"2021","unstructured":"Bou-Dargham MJ, Draughon S, Cantrell V, Khamis ZI, Sang QXA. Advancements in human breast cancer targeted therapy and immunotherapy. J Cancer. 2021;12:6949. https:\/\/doi.org\/10.7150\/JCA.64205.","journal-title":"J Cancer"},{"key":"1396_CR3","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/S00404-025-08028-0","volume":"312","author":"N Tauber","year":"2025","unstructured":"Tauber N, Amann N, Dannehl D, Deutsch TM, Dimpfl M, Fasching P, et al. Therapy of early breast cancer: current status and perspectives. Arch Gynecol Obstet. 2025;312:311\u201328. https:\/\/doi.org\/10.1007\/S00404-025-08028-0.","journal-title":"Arch Gynecol Obstet"},{"key":"1396_CR4","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.21037\/APM-24-64","volume":"13","author":"S Vuong","year":"2024","unstructured":"Vuong S, Warner E. Breast Cancer survivorship among younger patients: challenges and opportunities-narrative review. Ann Palliat Med. 2024;13:1246\u201357. https:\/\/doi.org\/10.21037\/APM-24-64.","journal-title":"Ann Palliat Med"},{"key":"1396_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/S40487-023-00225-8","volume":"11","author":"D Soldato","year":"2023","unstructured":"Soldato D, Arecco L, Agostinetto E, Franzoi MA, Mariamidze E, Begijanashvili S, et al. The future of breast cancer research in the survivorship field. Oncol Ther. 2023;11:199. https:\/\/doi.org\/10.1007\/S40487-023-00225-8.","journal-title":"Oncol Ther"},{"issue":"1","key":"1396_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-54961-6","volume":"14","author":"S Mannion","year":"2024","unstructured":"Mannion S, Higgins A, Larson N, Stewart EA, Khan Z, Shenoy C, et al. Prevalence and impact of fertility concerns in young women with breast cancer. Sci Rep. 2024;14(1):4418. https:\/\/doi.org\/10.1038\/s41598-024-54961-6.","journal-title":"Sci Rep"},{"key":"1396_CR7","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/j.annonc.2020.09.006","volume":"31","author":"M Lambertini","year":"2020","unstructured":"Lambertini M, Peccatori FA, Demeestere I, Amant F, Wyns C, Stukenborg JB, et al. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO clinical practice guidelines. Ann Oncol. 2020;31:1664\u201378. https:\/\/doi.org\/10.1016\/j.annonc.2020.09.006.","journal-title":"Ann Oncol"},{"key":"1396_CR8","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1200\/JCO-24-02782","volume":"43","author":"HI Su","year":"2025","unstructured":"Su HI, Lacchetti C, Letourneau J, Partridge AH, Qamar R, Quinn GP, et al. Fertility preservation in people with cancer: ASCO guideline update. J Clin Oncol. 2025;43:1488\u2013515. https:\/\/doi.org\/10.1200\/JCO-24-02782.","journal-title":"J Clin Oncol"},{"key":"1396_CR9","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1200\/OP-24-00634","volume":"21","author":"L Arecco","year":"2025","unstructured":"Arecco L, Omar A, de Moura Leite L, Jankovi\u0107 K, Gentile G, Stana M, et al. The value of offering oncofertility counseling in young patients with newly diagnosed cancer is unquestionable. JCO Oncol Pract. 2025;21:578\u20139. https:\/\/doi.org\/10.1200\/OP-24-00634.","journal-title":"JCO Oncol Pract"},{"key":"1396_CR10","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2147\/TCRM.S1566","volume":"4","author":"JMA Nabholtz","year":"2008","unstructured":"Nabholtz JMA. Long-term safety of aromatase inhibitors in the treatment of breast cancer. Ther Clin Risk Manag. 2008;4:189\u2013204. https:\/\/doi.org\/10.2147\/TCRM.S1566.","journal-title":"Ther Clin Risk Manag"},{"key":"1396_CR11","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","volume":"378","author":"O Abe","year":"2011","unstructured":"Abe O, Abe R, Enomoto K, Kikuchi K, Koyama H, Masuda H, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(11)60993-8.","journal-title":"Lancet"},{"key":"1396_CR12","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1200\/JCO.2009.23.1274","volume":"28","author":"M Dowsett","year":"2010","unstructured":"Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010;28:509\u201318. https:\/\/doi.org\/10.1200\/JCO.2009.23.1274.","journal-title":"J Clin Oncol"},{"key":"1396_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/S12885-020-6549-5","volume":"20","author":"R Yamazaki","year":"2020","unstructured":"Yamazaki R, Inokuchi M, Ishikawa S, Ayabe T, Jinno H, Iizuka T, et al. Ovarian hyperstimulation closely associated with resumption of follicular growth after chemotherapy during tamoxifen treatment in premenopausal women with breast cancer: a multicenter retrospective cohort study. BMC Cancer. 2020;20:67. https:\/\/doi.org\/10.1186\/S12885-020-6549-5.","journal-title":"BMC Cancer"},{"key":"1396_CR14","doi-asserted-by":"publisher","unstructured":"Berliere M, Duhoux FP, Dalenc F, Baurain JF, Dellevigne L, Galant C, et al. Tamoxifen and ovarian function. PLoS ONE. 2013. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0066616.","DOI":"10.1371\/JOURNAL.PONE.0066616"},{"key":"1396_CR15","first-page":"1026","volume":"15","author":"PM Ravdin","year":"1988","unstructured":"Ravdin PM, Fritz NF, Tormey DC, Jordan VC. Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen. Cancer Res. 1988;15:1026\u20139.","journal-title":"Cancer Res"},{"key":"1396_CR16","first-page":"624","volume":"15","author":"VC Jordan","year":"1987","unstructured":"Jordan VC, Fritz NF, Tormey DC. Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer. Cancer Res. 1987;15:624\u201330.","journal-title":"Cancer Res"},{"key":"1396_CR17","doi-asserted-by":"publisher","DOI":"10.3802\/JGO.2017.28.E10","author":"H Kim","year":"2017","unstructured":"Kim H, Han W, Ku SY, Suh CS, Kim SH, Choi YM. Feature of amenorrhea in postoperative tamoxifen users with breast cancer. J Gynecol Oncol. 2017. https:\/\/doi.org\/10.3802\/JGO.2017.28.E10.","journal-title":"J Gynecol Oncol"},{"key":"1396_CR18","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1093\/JNCI\/83.20.1488","volume":"83","author":"VC Jordan","year":"1991","unstructured":"Jordan VC, Fritz NF, Langan-Fahey S, Thompson M, Tormey DC. Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent. J Natl Cancer Inst. 1991;83:1488\u201391. https:\/\/doi.org\/10.1093\/JNCI\/83.20.1488.","journal-title":"J Natl Cancer Inst"},{"key":"1396_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/S13048-019-0581-6","volume":"12","author":"C Silva","year":"2019","unstructured":"Silva C, Ribeiro Rama AC, Reis Soares S, Moura-Ramos M, Almeida-Santos T. Adverse reproductive health outcomes in a cohort of young women with breast cancer exposed to systemic treatments. J Ovarian Res. 2019;12:102. https:\/\/doi.org\/10.1186\/S13048-019-0581-6.","journal-title":"J Ovarian Res"},{"key":"1396_CR20","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ejca.2017.03.035","volume":"79","author":"A Dezellus","year":"2017","unstructured":"Dezellus A, Barriere P, Campone M, Lemanski C, Vanlemmens L, Mignot L, et al. Prospective evaluation of serum anti-M\u00fcllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer. Eur J Cancer. 2017;79:72\u201380. https:\/\/doi.org\/10.1016\/j.ejca.2017.03.035.","journal-title":"Eur J Cancer"},{"key":"1396_CR21","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ejca.2017.10.001","volume":"87","author":"RA Anderson","year":"2017","unstructured":"Anderson RA, Mansi J, Coleman RE, Adamson DJA, Leonard RCF. The utility of anti-M\u00fcllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer. Eur J Cancer. 2017;87:58\u201364. https:\/\/doi.org\/10.1016\/j.ejca.2017.10.001.","journal-title":"Eur J Cancer"},{"key":"1396_CR22","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/S10549-015-3511-3","volume":"153","author":"AJ Chien","year":"2015","unstructured":"Chien AJ, Duralde E, Hwang R, Tsung K, Kao CN, Rugo HS, et al. Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer. Breast Cancer Res Treat. 2015;153:173\u201381. https:\/\/doi.org\/10.1007\/S10549-015-3511-3.","journal-title":"Breast Cancer Res Treat"},{"key":"1396_CR23","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1200\/JCO.2005.03.0783","volume":"24","author":"M Colleoni","year":"2006","unstructured":"Colleoni M, Gelber S, Goldhirsch A, Aebi S, Castiglione-Gertsch M, Price K, et al. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13\u201393. J Clin Oncol. 2006;24:1332\u201341. https:\/\/doi.org\/10.1200\/JCO.2005.03.0783.","journal-title":"J Clin Oncol"},{"key":"1396_CR24","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/S10549-008-9937-0","volume":"113","author":"SM Swain","year":"2009","unstructured":"Swain SM, Land SR, Ritter MW, Costantino JP, Cecchini RS, Mamounas EP, et al. Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial. Breast Cancer Res Treat. 2009;113:315\u201320. https:\/\/doi.org\/10.1007\/S10549-008-9937-0.","journal-title":"Breast Cancer Res Treat"},{"key":"1396_CR25","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1200\/JCO.1999.17.8.2365","volume":"17","author":"PJ Goodwin","year":"1999","unstructured":"Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol. 1999;17:2365\u201370. https:\/\/doi.org\/10.1200\/JCO.1999.17.8.2365.","journal-title":"J Clin Oncol"},{"key":"1396_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-281","volume":"10","author":"WB Zhou","year":"2010","unstructured":"Zhou WB, Yin H, Liu XA, Zha XM, Chen L, Dai JC, et al. Incidence of chemotherapy-induced amenorrhea associated with epirubicin, docetaxel and Navelbine in younger breast cancer patients. BMC Cancer. 2010;10:281. https:\/\/doi.org\/10.1186\/1471-2407-10-281.","journal-title":"BMC Cancer"},{"key":"1396_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2022.859974\/FULL","volume":"12","author":"Y Wang","year":"2022","unstructured":"Wang Y, Li Y, Liang J, Zhang N, Yang Q. Chemotherapy-induced amenorrhea and its prognostic significance in premenopausal women with breast cancer: an updated meta-analysis. Front Oncol. 2022;12:859974. https:\/\/doi.org\/10.3389\/FONC.2022.859974\/FULL.","journal-title":"Front Oncol"},{"key":"1396_CR28","doi-asserted-by":"publisher","first-page":"664","DOI":"10.3109\/0284186X.2016.1155738","volume":"55","author":"A Zavos","year":"2016","unstructured":"Zavos A, Valachis A. Risk of chemotherapy-induced amenorrhea in patients with breast cancer: a systematic review and meta-analysis. Acta Oncol. 2016;55:664\u201370. https:\/\/doi.org\/10.3109\/0284186X.2016.1155738.","journal-title":"Acta Oncol"},{"key":"1396_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/S41523-021-00307-8","author":"PD Poorvu","year":"2021","unstructured":"Poorvu PD, Hu J, Zheng Y, Gelber SI, Ruddy KJ, Tamimi RM, et al. Treatment-related amenorrhea in a modern, prospective cohort study of young women with breast cancer. NPJ Breast Cancer. 2021. https:\/\/doi.org\/10.1038\/S41523-021-00307-8.","journal-title":"NPJ Breast Cancer"},{"key":"1396_CR30","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1200\/JCO.2005.03.3969","volume":"24","author":"JA Petrek","year":"2006","unstructured":"Petrek JA, Naughton MJ, Case LD, Paskett ED, Naftalis EZ, Singletary SE, et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol. 2006;24:1045\u201351. https:\/\/doi.org\/10.1200\/JCO.2005.03.3969.","journal-title":"J Clin Oncol"},{"key":"1396_CR31","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/CNCR.24835","volume":"116","author":"ME Abusief","year":"2010","unstructured":"Abusief ME, Missmer SA, Ginsburg ES, Weeks JC, Partridge AH. The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. Cancer. 2010;116:791\u20138. https:\/\/doi.org\/10.1002\/CNCR.24835.","journal-title":"Cancer"},{"key":"1396_CR32","first-page":"147","volume":"6","author":"L Pourali","year":"2013","unstructured":"Pourali L, Kermani Taghizadeh A, Ghavamnasiri MR, Khoshroo F, Hosseini S, Asadi M, et al. Incidence of chemotherapy-induced amenorrhea after adjuvant chemotherapy with taxane and anthracyclines in young patients with breast cancer. Iran J Cancer Prev. 2013;6:147.","journal-title":"Iran J Cancer Prev"},{"key":"1396_CR33","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ejca.2021.03.017","volume":"151","author":"HJ Kim","year":"2021","unstructured":"Kim HJ, Noh WC, Nam SJ, Park BW, Lee ES, Im SA, et al. Five-year changes in ovarian function restoration in premenopausal patients with breast cancer taking tamoxifen after chemotherapy: an ASTRRA study report. Eur J Cancer. 2021;151:190\u2013200. https:\/\/doi.org\/10.1016\/j.ejca.2021.03.017.","journal-title":"Eur J Cancer"},{"key":"1396_CR34","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1093\/annonc\/mds006","volume":"23","author":"IH Park","year":"2012","unstructured":"Park IH, Han HS, Lee H, Lee KS, Kang HS, Lee S, et al. Resumption or persistence of menstruation after cytotoxic chemotherapy is a prognostic factor for poor disease-free survival in premenopausal patients with early breast cancer. Ann Oncol. 2012;23:2283\u20139. https:\/\/doi.org\/10.1093\/annonc\/mds006.","journal-title":"Ann Oncol"},{"key":"1396_CR35","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.fertnstert.2016.10.020","volume":"107","author":"LM Shandley","year":"2017","unstructured":"Shandley LM, Spencer JB, Fothergill A, Mertens AC, Manatunga A, Paplomata E, et al. Impact of tamoxifen therapy on fertility in breast cancer survivors. Fertil Steril. 2017;107:243-252.e5. https:\/\/doi.org\/10.1016\/j.fertnstert.2016.10.020.","journal-title":"Fertil Steril"},{"key":"1396_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2024.103776","author":"A Dezellus","year":"2024","unstructured":"Dezellus A, Mirallie S, Leperlier F, Sauterey B, Bouet PE, Dessaint A, et al. Use of tamoxifene-controlled ovarian hyperstimulation for fertility preservation before breast cancer treatment: a prospective cohort study with a 5-year follow-up. Breast. 2024. https:\/\/doi.org\/10.1016\/j.breast.2024.103776.","journal-title":"Breast"},{"key":"1396_CR37","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/S10549-019-05154-7","volume":"175","author":"TN Schuurman","year":"2019","unstructured":"Schuurman TN, Witteveen PO, van der Wall E, Passier JLM, Huitema ADR, Amant F, et al. Tamoxifen and pregnancy: an absolute contraindication? Breast Cancer Res Treat. 2019;175:17\u201325. https:\/\/doi.org\/10.1007\/S10549-019-05154-7.","journal-title":"Breast Cancer Res Treat"},{"key":"1396_CR38","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1634\/THEONCOLOGIST.2011-0121","volume":"16","author":"G Braems","year":"2011","unstructured":"Braems G, Denys H, De Wever O, Cocquyt V, Van den Broecke R. Use of tamoxifen before and during pregnancy. Oncologist. 2011;16:1547\u201351. https:\/\/doi.org\/10.1634\/THEONCOLOGIST.2011-0121.","journal-title":"Oncologist"},{"key":"1396_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2023.1249160","author":"D Generali","year":"2023","unstructured":"Generali D, Berardi R, Caruso M, Cazzaniga M, Garrone O, Minchella I, et al. Aromatase inhibitors: the journey from the state of the art to clinical open questions. Front Oncol. 2023. https:\/\/doi.org\/10.3389\/FONC.2023.1249160.","journal-title":"Front Oncol"},{"key":"1396_CR40","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/S10549-023-07054-3","volume":"201","author":"M Faltinov\u00e1","year":"2023","unstructured":"Faltinov\u00e1 M, Vehmanen L, Lyytinen H, Haanp\u00e4\u00e4 M, H\u00e4m\u00e4l\u00e4inen E, Tiitinen A, et al. Effects of letrozole on serum estradiol and estrone in postmenopausal breast cancer patients and tolerability of treatment: a prospective trial using a highly sensitive LC\u2013MS\/MS (liquid chromatography\u2013tandem mass spectrometry) method for estrogen measurement. Breast Cancer Res Treat. 2023;201:425\u201335. https:\/\/doi.org\/10.1007\/S10549-023-07054-3.","journal-title":"Breast Cancer Res Treat"},{"key":"1396_CR41","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3109\/13697137.2014.929105","volume":"18","author":"I Kyvernitakis","year":"2015","unstructured":"Kyvernitakis I, Albert US, Kalder M, Winarno AS, Hars O, Hadji P. Effect of anastrozole on hormone levels in postmenopausal women with early breast cancer. Climacteric. 2015;18:63\u20138. https:\/\/doi.org\/10.3109\/13697137.2014.929105.","journal-title":"Climacteric"},{"key":"1396_CR42","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1038\/BJC.2013.499","volume":"109","author":"G Pfeiler","year":"2013","unstructured":"Pfeiler G, K\u00f6nigsberg R, Hadji P, Fitzal F, Maroske M, Dressel-Ban G, et al. Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer. Br J Cancer. 2013;109:1522\u20137. https:\/\/doi.org\/10.1038\/BJC.2013.499.","journal-title":"Br J Cancer"},{"key":"1396_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/S12885-017-3208-6","volume":"17","author":"A Oberguggenberger","year":"2017","unstructured":"Oberguggenberger A, Meraner V, Sztankay M, Beer B, Weigel G, Oberacher H, et al. Can we use gonadotropin plasma concentration as surrogate marker for BMI-related incomplete estrogen suppression in breast cancer patients receiving anastrozole? BMC Cancer. 2017;17:226. https:\/\/doi.org\/10.1186\/S12885-017-3208-6.","journal-title":"BMC Cancer"},{"key":"1396_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbmo.2025.104878","volume":"51","author":"D Lifshitz","year":"2025","unstructured":"Lifshitz D, Ben-Haroush A, Meirow D, Orvieto R, Meirman DV, Elbaz L, et al. Letrozole or tamoxifen co-administration during fertility preservation for patients affected by breast cancer. Reprod Biomed Online. 2025;51:104878. https:\/\/doi.org\/10.1016\/j.rbmo.2025.104878.","journal-title":"Reprod Biomed Online"},{"key":"1396_CR45","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1210\/JC.2007-0247","volume":"92","author":"AA Azim","year":"2007","unstructured":"Azim AA, Costantini-Ferrando M, Lostritto K, Oktay K. Relative potencies of anastrozole and letrozole to suppress estradiol in breast cancer patients undergoing ovarian stimulation before in vitro fertilization. J Clin Endocrinol Metab. 2007;92:2197\u2013200. https:\/\/doi.org\/10.1210\/JC.2007-0247.","journal-title":"J Clin Endocrinol Metab"},{"key":"1396_CR46","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/S10549-024-07411-W","volume":"208","author":"SWM Lammers","year":"2024","unstructured":"Lammers SWM, Geurts SME, Hermans KEPE, van Hellemond IEG, Swinkels ACP, Smorenburg CH, et al. Ovarian function recovery in breast cancer patients receiving adjuvant anastrozole treatment: updated results from the Phase 3 DATA trial. Breast Cancer Res Treat. 2024;208:179\u201392. https:\/\/doi.org\/10.1007\/S10549-024-07411-W.","journal-title":"Breast Cancer Res Treat"},{"key":"1396_CR47","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1200\/JCO.2015.62.2985","volume":"34","author":"LK Krekow","year":"2016","unstructured":"Krekow LK, Hellerstedt BA, Collea RP, Papish S, Diggikar SM, Resta R, et al. Incidence and predictive factors for recovery of ovarian function in amenorrheic women in their 40s treated with letrozole. J Clin Oncol. 2016;34:1594\u2013600. https:\/\/doi.org\/10.1200\/JCO.2015.62.2985.","journal-title":"J Clin Oncol"},{"key":"1396_CR48","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1093\/annonc\/mdt149","volume":"24","author":"NL Henry","year":"2013","unstructured":"Henry NL, Xia R, Banerjee M, Gersch C, McConnell D, Giacherio D, et al. Predictors of recovery of ovarian function during aromatase inhibitor therapy. Ann Oncol. 2013;24:2011\u20136. https:\/\/doi.org\/10.1093\/annonc\/mdt149.","journal-title":"Ann Oncol"},{"key":"1396_CR49","doi-asserted-by":"publisher","first-page":"3885","DOI":"10.1210\/JC.2006-0962","volume":"91","author":"K Oktay","year":"2006","unstructured":"Oktay K, Hourvitz A, Sahin G, Oktem O, Safro B, Cil A, et al. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J Clin Endocrinol Metab. 2006;91:3885\u201390. https:\/\/doi.org\/10.1210\/JC.2006-0962.","journal-title":"J Clin Endocrinol Metab"},{"key":"1396_CR50","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1200\/JCO.2014.59.3723","volume":"33","author":"K Oktay","year":"2015","unstructured":"Oktay K, Turan V, Bedoschi G, Pacheco FS, Moy F. Fertility preservation success subsequent to concurrent aromatase inhibitor treatment and ovarian stimulation in women with breast cancer. J Clin Oncol. 2015;33:2424\u20139. https:\/\/doi.org\/10.1200\/JCO.2014.59.3723.","journal-title":"J Clin Oncol"},{"key":"1396_CR51","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1080\/09513590.2018.1534950","volume":"35","author":"A Ben-Haroush","year":"2019","unstructured":"Ben-Haroush A, Wertheimer A, Klochendler E, Sapir O, Shufaro Y, Oron G. Effect of letrozole added to gonadotropins in controlled ovarian stimulation protocols on the yield and maturity of retrieved oocytes. Gynecol Endocrinol. 2019;35:324\u20137. https:\/\/doi.org\/10.1080\/09513590.2018.1534950.","journal-title":"Gynecol Endocrinol"},{"key":"1396_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/S13048-022-01073-2","volume":"15","author":"F Kasuga-Yamashita","year":"2022","unstructured":"Kasuga-Yamashita F, Baba T, Nagao S, Fujibe Y, Morishita M, Kuno Y, et al. Letrozole increases preantral follicle growth and decreases estradiol production without impairing follicle survival. J Ovarian Res. 2022;15:01073\u20132. https:\/\/doi.org\/10.1186\/S13048-022-01073-2.","journal-title":"J Ovarian Res"},{"key":"1396_CR53","doi-asserted-by":"publisher","DOI":"10.1095\/BIOLREPROD.115.131631","volume":"93","author":"AS Kauffman","year":"2015","unstructured":"Kauffman AS, Thackray VG, Ryan GE, Tolson KP, Glidewell-Kenney CA, Semaan SJ, et al. A novel Letrozole model recapitulates both the reproductive and metabolic phenotypes of Polycystic Ovary Syndrome in female mice. Biol Reprod. 2015;93:131631. https:\/\/doi.org\/10.1095\/BIOLREPROD.115.131631.","journal-title":"Biol Reprod"},{"key":"1396_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/J.XFRE.2022.03.001","volume":"3","author":"K Takeshima","year":"2022","unstructured":"Takeshima K, Ezoe K, Kawasaki N, Hayashi H, Kuroda T, Kato K. Perinatal outcomes and congenital anomalies associated with Letrozole and natural cycles in single fresh cleaved embryo transfers: a single-center, 10-year cohort study. F S Rep. 2022;3:138. https:\/\/doi.org\/10.1016\/J.XFRE.2022.03.001.","journal-title":"F S Rep"},{"key":"1396_CR55","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0108219","volume":"9","author":"S Sharma","year":"2014","unstructured":"Sharma S, Ghosh S, Singh S, Chakravarty A, Ganesh A, Rajani S, et al. Congenital malformations among babies born following Letrozole or Clomiphene for infertility treatment. PLoS One. 2014;9:0108219. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0108219.","journal-title":"PLoS One"},{"key":"1396_CR56","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3892\/ETM.2024.12596","volume":"28","author":"B Wang","year":"2024","unstructured":"Wang B, Lin H, Xia R, Lin S, Li Z. Evaluation of birth outcomes, congenital anomalies and neonatal complications of singletons born to infertile women treated with Letrozole: a retrospective cohort study. Exp Ther Med. 2024;28:307. https:\/\/doi.org\/10.3892\/ETM.2024.12596.","journal-title":"Exp Ther Med"},{"key":"1396_CR57","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/HUMUPD\/DMAA055","volume":"27","author":"J Pundir","year":"2021","unstructured":"Pundir J, Achilli C, Bhide P, Sabatini L, Legro RS, Rombauts L, et al. Risk of foetal harm with Letrozole use in fertility treatment: a systematic review and meta-analysis. Hum Reprod Update. 2021;27:474\u201385. https:\/\/doi.org\/10.1093\/HUMUPD\/DMAA055.","journal-title":"Hum Reprod Update"},{"key":"1396_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/J.XCRM.2024.101575","volume":"5","author":"E Agostinetto","year":"2024","unstructured":"Agostinetto E, Curigliano G, Piccart M. Emerging treatments in HER2-Positive advanced breast cancer: keep raising the bar. Cell Rep Med. 2024;5:101575. https:\/\/doi.org\/10.1016\/J.XCRM.2024.101575.","journal-title":"Cell Rep Med"},{"key":"1396_CR59","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/S41573-022-00579-0","volume":"22","author":"SM Swain","year":"2023","unstructured":"Swain SM, Shastry M, Hamilton E. Targeting HER2-Positive breast cancer: advances and future directions. Nat Rev Drug Discov. 2023;22:101\u201326. https:\/\/doi.org\/10.1038\/S41573-022-00579-0.","journal-title":"Nat Rev Drug Discov"},{"key":"1396_CR60","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/S41523-021-00264-2","volume":"7","author":"PA Ganz","year":"2021","unstructured":"Ganz PA, Cecchini RS, Fehrenbacher L, Geyer CE, Rastogi P, Crown JP, et al. NRG Oncology\/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without Trastuzumab. npj Breast Cancer. 2021;7:55. https:\/\/doi.org\/10.1038\/S41523-021-00264-2.","journal-title":"npj Breast Cancer"},{"key":"1396_CR61","doi-asserted-by":"publisher","first-page":"e494","DOI":"10.3747\/CO.24.3335","volume":"24","author":"K Morarji","year":"2017","unstructured":"Morarji K, McArdle O, Hui K, Gingras-Hill G, Ahmed S, Greenblatt EM, et al. Ovarian function after chemotherapy in young breast cancer survivors. Curr Oncol. 2017;24:e494. https:\/\/doi.org\/10.3747\/CO.24.3335.","journal-title":"Curr Oncol"},{"key":"1396_CR62","doi-asserted-by":"publisher","first-page":"DJY094","DOI":"10.1093\/JNCI\/DJY094","volume":"111","author":"M Lambertini","year":"2019","unstructured":"Lambertini M, Campbell C, Bines J, Korde LA, Izquierdo M, Fumagalli D, et al. Adjuvant anti-HER2 therapy, treatment-related amenorrhea, and survival in premenopausal HER2-positive early breast cancer patients. J Natl Cancer Inst. 2019;111:DJY094. https:\/\/doi.org\/10.1093\/JNCI\/DJY094.","journal-title":"J Natl Cancer Inst"},{"key":"1396_CR63","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/S10549-015-3426-Z","volume":"151","author":"KJ Ruddy","year":"2015","unstructured":"Ruddy KJ, Guo H, Barry W, Dang CT, Yardley DA, Moy B, et al. Chemotherapy-related amenorrhea after adjuvant Paclitaxel-Trastuzumab (APT trial). Breast Cancer Res Treat. 2015;151:589\u201396. https:\/\/doi.org\/10.1007\/S10549-015-3426-Z.","journal-title":"Breast Cancer Res Treat"},{"key":"1396_CR64","doi-asserted-by":"publisher","first-page":"33","DOI":"10.6004\/JNCCN.2022.7065","volume":"21","author":"M Lambertini","year":"2023","unstructured":"Lambertini M, Ceppi M, Anderson RA, Cameron DA, Bruzzone M, Franzoi MA, et al. Impact of anti-HER2 therapy alone and with weekly paclitaxel on the ovarian reserve of young women with HER2-positive breast cancer. J Natl Compr Canc Netw. 2023;21:33\u201341. https:\/\/doi.org\/10.6004\/JNCCN.2022.7065.","journal-title":"J Natl Compr Canc Netw"},{"key":"1396_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/BIOMEDICINES8120577","volume":"8","author":"M Levi","year":"2020","unstructured":"Levi M, Goshen-Lago T, Yerushalmi R, Granot T, Stemmer SM, Shalgi R, et al. Anti-HER2\/Neu antibody reduces chemotherapy-induced ovarian toxicity-from bench to bedside. Biomedicines. 2020;8:1\u201311. https:\/\/doi.org\/10.3390\/BIOMEDICINES8120577.","journal-title":"Biomedicines"},{"key":"1396_CR66","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/S10549-021-06267-8","volume":"189","author":"KJ Ruddy","year":"2021","unstructured":"Ruddy KJ, Zheng Y, Tayob N, Hu J, Dang CT, Yardley DA, et al. Chemotherapy-related amenorrhea (CRA) after adjuvant Ado-Trastuzumab Emtansine (T-DM1) compared to Paclitaxel in combination with Trastuzumab (TH) (TBCRC033: ATEMPT Trial). Breast Cancer Res Treat. 2021;189:103\u201310. https:\/\/doi.org\/10.1007\/S10549-021-06267-8.","journal-title":"Breast Cancer Res Treat"},{"key":"1396_CR67","doi-asserted-by":"publisher","first-page":"47201","DOI":"10.7759\/CUREUS.47201","volume":"15","author":"HO Al-shamsi","year":"2023","unstructured":"Al-shamsi HO, Abdelwahed N, Singh M, Abyad AM, Elsabae S, Abdelgawad T, et al. First reported case of successful conception and delivery during stage IV breast cancer treatment: a case report and literature review. Cureus. 2023;15:47201. https:\/\/doi.org\/10.7759\/CUREUS.47201.","journal-title":"Cureus"},{"key":"1396_CR68","doi-asserted-by":"publisher","first-page":"9329","DOI":"10.1186\/1757-1626-2-9329","volume":"2","author":"MJ Goodyer","year":"2009","unstructured":"Goodyer MJ, Ismail JRM, O\u2019Reilly SP, Moylan EJ, Ryan CAM, Hughes PAF, et al. Safety of trastuzumab (Herceptin) during pregnancy: two case reports. Cases J. 2009;2:9329. https:\/\/doi.org\/10.1186\/1757-1626-2-9329.","journal-title":"Cases J"},{"key":"1396_CR69","doi-asserted-by":"publisher","DOI":"10.14740\/WJON919W","volume":"6","author":"N Pianca","year":"2015","unstructured":"Pianca N, Shafiei M, George M. Trastuzumab exposure in early pregnancy for a young lady with locally invasive breast cancer. World J Oncol. 2015;6:381. https:\/\/doi.org\/10.14740\/WJON919W.","journal-title":"World J Oncol"},{"key":"1396_CR70","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/S10549-012-1996-6","volume":"133","author":"HA Azim","year":"2012","unstructured":"Azim HA, Metzger-Filho O, De Azambuja E, Loibl S, Focant F, Gresko E, et al. Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA Trial (BIG 01-01). Breast Cancer Res Treat. 2012;133:387\u201391. https:\/\/doi.org\/10.1007\/S10549-012-1996-6.","journal-title":"Breast Cancer Res Treat"},{"key":"1396_CR71","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/CNCR.31784","volume":"125","author":"M Lambertini","year":"2019","unstructured":"Lambertini M, Martel S, Campbell C, Guillaume S, Hilbers FS, Schuehly U, et al. Pregnancies during and after trastuzumab and\/or lapatinib in patients with Human Epidermal Growth Factor Receptor 2-positive early breast cancer: analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials. Cancer. 2019;125:307\u201316. https:\/\/doi.org\/10.1002\/CNCR.31784.","journal-title":"Cancer"},{"key":"1396_CR72","doi-asserted-by":"publisher","DOI":"10.1001\/JAMANETWORKOPEN.2023.39934","volume":"6","author":"P Gougis","year":"2023","unstructured":"Gougis P, Grandal B, Jochum F, Bihan K, Coussy F, Barraud S, et al. Treatments during pregnancy targeting ERBB2 and outcomes of pregnant individuals and newborns. JAMA Netw Open. 2023;6:E2339934. https:\/\/doi.org\/10.1001\/JAMANETWORKOPEN.2023.39934.","journal-title":"JAMA Netw Open"},{"key":"1396_CR73","doi-asserted-by":"publisher","first-page":"08162","DOI":"10.1186\/S12885-021-08162-3","volume":"21","author":"A Andrikopoulou","year":"2021","unstructured":"Andrikopoulou A, Apostolidou K, Chatzinikolaou S, Bletsa G, Zografos E, Dimopoulos MA, et al. Trastuzumab administration during pregnancy: an update. BMC Cancer. 2021;21:08162\u20133. https:\/\/doi.org\/10.1186\/S12885-021-08162-3.","journal-title":"BMC Cancer"},{"key":"1396_CR74","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS15071987","volume":"15","author":"MF Mercogliano","year":"2023","unstructured":"Mercogliano MF, Bruni S, Mauro FL, Schillaci R. Emerging targeted therapies for HER2-positive breast cancer. Cancers (Basel). 2023;15:15071987. https:\/\/doi.org\/10.3390\/CANCERS15071987.","journal-title":"Cancers (Basel)"},{"key":"1396_CR75","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1200\/JCO.20.03398","volume":"39","author":"SM Tolaney","year":"2021","unstructured":"Tolaney SM, Tayob N, Dang C, Yardley DA, Isakoff SJ, Valero V, et al. Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT): a randomized clinical trial. J Clin Oncol. 2021;39:2375\u201385. https:\/\/doi.org\/10.1200\/JCO.20.03398.","journal-title":"J Clin Oncol"},{"key":"1396_CR76","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1021\/ACS.BIOCONJCHEM.5B00223","volume":"26","author":"TM Cardillo","year":"2015","unstructured":"Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Arrojo R, Liu D, et al. Sacituzumab Govitecan (IMMU-132), an anti-Trop-2\/SN-38 antibody-drug conjugate: characterization and efficacy in pancreatic, gastric, and other cancers. Bioconjug Chem. 2015;26:919\u201331. https:\/\/doi.org\/10.1021\/ACS.BIOCONJCHEM.5B00223.","journal-title":"Bioconjug Chem"},{"key":"1396_CR77","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/S41573-023-00709-2","volume":"22","author":"C Dumontet","year":"2023","unstructured":"Dumontet C, Reichert JM, Senter PD, Lambert JM, Beck A. Antibody-drug conjugates come of age in oncology. Nat Rev Drug Discov. 2023;22:641\u201361. https:\/\/doi.org\/10.1038\/S41573-023-00709-2.","journal-title":"Nat Rev Drug Discov"},{"key":"1396_CR78","unstructured":"European Medicines Agency. Enhertu (Trastuzumab Deruxtecan): Summary of product characteristics. Amsterdam: European Medicines Agency. 2025. https:\/\/ema.europa.eu\/en\/medicines\/human\/EPAR\/enhertu"},{"key":"1396_CR79","unstructured":"European Medicines Agency. Trodelvy (Sacituzumab Govitecan): Summary of product characteristics. Amsterdam: European Medicines Agency. 2025. https:\/\/ema.europa.eu\/en\/medicines\/human\/EPAR\/trodelvy"},{"key":"1396_CR80","doi-asserted-by":"publisher","DOI":"10.1007\/S11864-023-01087-Y","volume":"24","author":"J Dixon-Douglas","year":"2023","unstructured":"Dixon-Douglas J, Loi S. Immunotherapy in early-stage triple-negative breast cancer: where are we now and where are we headed? Curr Treat Options Oncol. 2023;24:1004. https:\/\/doi.org\/10.1007\/S11864-023-01087-Y.","journal-title":"Curr Treat Options Oncol"},{"key":"1396_CR81","doi-asserted-by":"publisher","DOI":"10.1186\/S12916-016-0623-5","author":"S Farkona","year":"2016","unstructured":"Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of cancer? BMC Med. 2016. https:\/\/doi.org\/10.1186\/S12916-016-0623-5.","journal-title":"BMC Med"},{"key":"1396_CR82","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_SUPPL.12014","volume":"41","author":"M Ogle","year":"2023","unstructured":"Ogle M, Harrold E, O\u2019Brien E, Weiss JA, Yaqubie A, Sinopoli JC, et al. Fertility post immune checkpoint blockade. J Clin Oncol. 2023;41:12014. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_SUPPL.12014.","journal-title":"J Clin Oncol"},{"key":"1396_CR83","doi-asserted-by":"publisher","DOI":"10.3390\/JPM14040431","author":"E Silvestris","year":"2024","unstructured":"Silvestris E, D\u2019Oronzo S, Petracca EA, D\u2019Addario C, Cormio G, Loizzi V, et al. Fertility preservation in the era of immuno-oncology: lights and shadows. J Pers Med. 2024. https:\/\/doi.org\/10.3390\/JPM14040431.","journal-title":"J Pers Med"},{"key":"1396_CR84","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.jaad.2016.04.031","volume":"75","author":"JR Walter","year":"2016","unstructured":"Walter JR, Xu S, Paller AS, Choi JN, Woodruff TK. Oncofertility considerations in adolescents and young adults given a diagnosis of melanoma: fertility risk of Food and Drug Administration\u2013Approved systemic therapies. J Am Acad Dermatol. 2016;75:528\u201334. https:\/\/doi.org\/10.1016\/j.jaad.2016.04.031.","journal-title":"J Am Acad Dermatol"},{"key":"1396_CR85","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1530\/JOE-21-0209","volume":"252","author":"PC Xu","year":"2021","unstructured":"Xu PC, Luan Y, Yu SY, Xu J, Coulter DW, Kim SY. Effects of PD-1 blockade on ovarian follicles in a prepubertal female mouse. J Endocrinol. 2021;252:15\u201330. https:\/\/doi.org\/10.1530\/JOE-21-0209.","journal-title":"J Endocrinol"},{"key":"1396_CR86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/S43018-022-00413-X","volume":"3","author":"AL Winship","year":"2022","unstructured":"Winship AL, Alesi LR, Sant S, Stringer JM, Cantavenera A, Hegarty T, et al. Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice. Nat Cancer. 2022;3:1\u201313. https:\/\/doi.org\/10.1038\/S43018-022-00413-X.","journal-title":"Nat Cancer"},{"key":"1396_CR87","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/S10549-025-07702-W","volume":"212","author":"A Perdrix","year":"2025","unstructured":"Perdrix A, Olympios N, Rouvet J, Degremont M, Fontaine C, Boitel B, et al. Impact of Pembrolizumab on ovarian function in young triple-negative breast cancer patients treated with chemo-immunotherapy. Breast Cancer Res Treat. 2025;212:79\u201386. https:\/\/doi.org\/10.1007\/S10549-025-07702-W.","journal-title":"Breast Cancer Res Treat"},{"key":"1396_CR88","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_SUPPL.12013","volume":"41","author":"EI Buchbinder","year":"2023","unstructured":"Buchbinder EI, Song Z, Lee SJ, Keefe KW, Manos MP, Tarhini AA, et al. Impact of immune checkpoint inhibition on ovarian reserve in patients with melanoma enrolled in the ECOG-ACRIN E1609 adjuvant trial. J Clin Oncol. 2023;41:12013\u201312013. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_SUPPL.12013.","journal-title":"J Clin Oncol"},{"key":"1396_CR89","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-6644","volume":"83","author":"A Hickman","year":"2023","unstructured":"Hickman A, Smith K, Khan Z, Enninga EA, Zhao Y, Cathcart-Rake E, et al. Abstract 6644: investigating the effect of immune checkpoint inhibitors (ICI) on ovarian function in young patients with melanoma. Cancer Res. 2023;83:6644\u20136644. https:\/\/doi.org\/10.1158\/1538-7445.AM2023-6644.","journal-title":"Cancer Res"},{"key":"1396_CR90","doi-asserted-by":"publisher","DOI":"10.1038\/S41598-025-91476-0","author":"B K\u00f6yl\u00fc","year":"2025","unstructured":"K\u00f6yl\u00fc B, Esen BH, Bekta\u015f \u015eN, \u00d6zbek L, Turan V, Urman B, et al. Pharmacovigilance analysis of immune checkpoint inhibitor-related reproductive adverse effects based on the FDA adverse event reporting system. Sci Rep. 2025. https:\/\/doi.org\/10.1038\/S41598-025-91476-0.","journal-title":"Sci Rep"},{"key":"1396_CR91","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/17446651.2023.2256405","volume":"18","author":"MJ Concepci\u00f3n-Zavaleta","year":"2023","unstructured":"Concepci\u00f3n-Zavaleta MJ, Coronado-Arroyo JC, Quiroz-Aldave JE, Durand-V\u00e1squez M, Ildefonso-Najarro SP, Rafael-Robles L, et al. Endocrine factors associated with infertility in women: an updated review. Expert Rev Endocrinol Metab. 2023;18:399\u2013417. https:\/\/doi.org\/10.1080\/17446651.2023.2256405.","journal-title":"Expert Rev Endocrinol Metab"},{"key":"1396_CR92","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.1210\/JC.2014-2306","volume":"99","author":"AT Faje","year":"2014","unstructured":"Faje AT, Sullivan R, Lawrence D, Tritos NA, Fadden R, Klibanski A, et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab. 2014;99:4078\u201385. https:\/\/doi.org\/10.1210\/JC.2014-2306.","journal-title":"J Clin Endocrinol Metab"},{"key":"1396_CR93","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1530\/EJE-14-0845","volume":"172","author":"F Albarel","year":"2015","unstructured":"Albarel F, Gaudy C, Castinetti F, Carr\u00e9 T, Morange I, Conte-Devolx B, et al. Long-term follow-up of Ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. Eur J Endocrinol. 2015;172:195\u2013204. https:\/\/doi.org\/10.1530\/EJE-14-0845.","journal-title":"Eur J Endocrinol"},{"key":"1396_CR94","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1056\/NEJMOA2409932","volume":"391","author":"P Schmid","year":"2024","unstructured":"Schmid P, Cortes J, Dent R, McArthur H, Pusztai L, K\u00fcmmel S, et al. Overall survival with Pembrolizumab in early-stage triple-negative breast cancer. N Engl J Med. 2024;391:1981\u201391. https:\/\/doi.org\/10.1056\/NEJMOA2409932.","journal-title":"N Engl J Med"},{"key":"1396_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2025.104473","author":"MO de Andrade","year":"2025","unstructured":"de Andrade MO, Gutierres IG, Tavares MC, de Sousa IM, Balint FC, Marin Comini AC, et al. Immune-related adverse events among patients with early-stage triple-negative breast cancer treated with pembrolizumab plus chemotherapy: real-world data from the neo-real\/GBECAM 0123 Study. Breast. 2025. https:\/\/doi.org\/10.1016\/j.breast.2025.104473.","journal-title":"Breast"},{"key":"1396_CR96","doi-asserted-by":"publisher","DOI":"10.1136\/JITC-2024-009902","volume":"12","author":"R Noseda","year":"2024","unstructured":"Noseda R, Bedussi F, Giunchi V, Fusaroli M, Raschi E, Ceschi A. Reporting of late-onset immune-related adverse events with immune checkpoint inhibitors in VigiBase. J Immunother Cancer. 2024;12:e009902. https:\/\/doi.org\/10.1136\/JITC-2024-009902.","journal-title":"J Immunother Cancer"},{"key":"1396_CR97","doi-asserted-by":"publisher","DOI":"10.1001\/JAMANETWORKOPEN.2025.2668","author":"SM Durbin","year":"2025","unstructured":"Durbin SM, Zubiri L, Perlman K, Wu CY, Lim T, Grealish K, et al. Late-onset immune-related adverse events after immune checkpoint inhibitor therapy. JAMA Netw Open. 2025. https:\/\/doi.org\/10.1001\/JAMANETWORKOPEN.2025.2668.","journal-title":"JAMA Netw Open"},{"key":"1396_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100248","author":"JC Hassel","year":"2021","unstructured":"Hassel JC, Livingstone E, Allam JP, Behre HM, Bojunga J, Klein HH, et al. Fertility preservation and management of pregnancy in melanoma patients requiring systemic therapy. ESMO Open. 2021. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100248.","journal-title":"ESMO Open"},{"key":"1396_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/J.ESMOOP.2021.100276","volume":"6","author":"M Garutti","year":"2021","unstructured":"Garutti M, Lambertini M, Puglisi F. Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review. ESMO Open. 2021;6:100276. https:\/\/doi.org\/10.1016\/J.ESMOOP.2021.100276.","journal-title":"ESMO Open"},{"key":"1396_CR100","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/EJI.201948382","volume":"50","author":"YH Zhang","year":"2020","unstructured":"Zhang YH, Sun HX. Immune checkpoint molecules in pregnancy: focus on regulatory T cells. Eur J Immunol. 2020;50:160\u20139. https:\/\/doi.org\/10.1002\/EJI.201948382.","journal-title":"Eur J Immunol"},{"key":"1396_CR101","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/BDRB.21176","volume":"107","author":"FM Poulet","year":"2016","unstructured":"Poulet FM, Wolf JJ, Herzyk DJ, Degeorge JJ. An evaluation of the impact of PD-1 pathway blockade on reproductive safety of therapeutic PD-1 inhibitors. Birth Defects Res B Dev Reprod Toxicol. 2016;107:108\u201319. https:\/\/doi.org\/10.1002\/BDRB.21176.","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"key":"1396_CR102","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS15010173","author":"R Noseda","year":"2022","unstructured":"Noseda R, M\u00fcller L, Bedussi F, Fusaroli M, Raschi E, Ceschi A. Immune checkpoint inhibitors and pregnancy: analysis of the VigiBase\u00ae spontaneous reporting system. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/CANCERS15010173.","journal-title":"Cancers (Basel)"},{"key":"1396_CR103","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1056\/NEJMOA2308135","volume":"389","author":"MA Baarslag","year":"2023","unstructured":"Baarslag MA, Heimovaara JH, Borgers JSW, van Aerde KJ, Koenen HJPM, Smeets RL, et al. Severe immune-related enteritis after in utero exposure to pembrolizumab. N Engl J Med. 2023;389:1790\u20136. https:\/\/doi.org\/10.1056\/NEJMOA2308135.","journal-title":"N Engl J Med"},{"key":"1396_CR104","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/CMR.0000000000000586","volume":"29","author":"W Xu","year":"2019","unstructured":"Xu W, Moor RJ, Walpole ET, Atkinson VG. Pregnancy with successful foetal and maternal outcome in a melanoma patient treated with nivolumab in the first trimester: case report and review of the literature. Melanoma Res. 2019;29:333\u20137. https:\/\/doi.org\/10.1097\/CMR.0000000000000586.","journal-title":"Melanoma Res"},{"key":"1396_CR105","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1200\/OP.22.00469","volume":"18","author":"AE Kim","year":"2022","unstructured":"Kim AE, Nelson A, Stimpert K, Flyckt RL, Thirumavalavan N, Baker KC, et al. Minding the bathwater: fertility and reproductive toxicity in the age of immuno-oncology. JCO Oncol Pract. 2022;18:815. https:\/\/doi.org\/10.1200\/OP.22.00469.","journal-title":"JCO Oncol Pract"},{"key":"1396_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.114028","author":"J Li","year":"2023","unstructured":"Li J, Li Q, Zhang L, Zhang S, Dai Y. Poly-ADP-Ribose Polymerase (PARP) inhibitors and ovarian function. Biomed Pharmacother. 2023. https:\/\/doi.org\/10.1016\/j.biopha.2022.114028.","journal-title":"Biomed Pharmacother"},{"key":"1396_CR107","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/S41416-023-02326-7","volume":"129","author":"D Bhamidipati","year":"2023","unstructured":"Bhamidipati D, Haro-Silerio JI, Yap TA, Ngoi N. PARP inhibitors: enhancing efficacy through rational combinations. Br J Cancer. 2023;129:904\u201316. https:\/\/doi.org\/10.1038\/S41416-023-02326-7.","journal-title":"Br J Cancer"},{"key":"1396_CR108","doi-asserted-by":"crossref","unstructured":"Nelson HD, Fu R, Goddard K, Mitchell JP, Okinaka-Hu L, Pappas M, Zakher B. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer. Risk Assess Genet Couns Genet Test BRCA-Related Cancer Syst Rev Updat US Prev Serv Task Force Recomm. Ann Intern Med. 2014;160(4):255\u201366. https:\/\/doi.org\/pubmed.ncbi.nlm.nih.gov\/24366442","DOI":"10.7326\/M13-1684"},{"key":"1396_CR109","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/S11523-021-00796-4","volume":"16","author":"L Cortesi","year":"2021","unstructured":"Cortesi L, Rugo HS, Jackisch C. An overview of PARP inhibitors for the treatment of breast cancer. Target Oncol. 2021;16:255\u201382. https:\/\/doi.org\/10.1007\/S11523-021-00796-4.","journal-title":"Target Oncol"},{"key":"1396_CR110","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1200\/JCO-24-01334","volume":"43","author":"M Lambertini","year":"2025","unstructured":"Lambertini M, Blondeaux E, Tomasello LM, Agostinetto E, Hamy AS, Kim HJ, et al. Clinical behavior of breast cancer in young BRCA carriers and prediagnostic awareness of germline BRCA status. J Clin Oncol. 2025;43:1706\u201319. https:\/\/doi.org\/10.1200\/JCO-24-01334.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1396_CR111","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS26062773","volume":"26","author":"K De","year":"2025","unstructured":"De K, Jana M, Chowdhury B, Calaf GM, Roy D. Role of PARP inhibitors: a new hope for breast cancer therapy. Int J Mol Sci. 2025;26(6):2773. https:\/\/doi.org\/10.3390\/IJMS26062773.","journal-title":"Int J Mol Sci"},{"key":"1396_CR112","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/j.annonc.2022.09.159","volume":"33","author":"CE Geyer","year":"2022","unstructured":"Geyer CE, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk. Early Breast Cancer Ann Oncol. 2022;33:1250\u201368. https:\/\/doi.org\/10.1016\/j.annonc.2022.09.159.","journal-title":"Early Breast Cancer Ann Oncol"},{"key":"1396_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104696","author":"F Zagouri","year":"2025","unstructured":"Zagouri F, Dimopoulos MA, Andrikopoulou A. PARP inhibitors during conception and pregnancy in breast cancer. Crit Rev Oncol Hematol. 2025. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104696.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1396_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/J.YDBIO.2009.05.550","volume":"331","author":"F Yang","year":"2009","unstructured":"Yang F, Baumann C, De La Fuente R. Persistence of histone H2AX phosphorylation after meiotic chromosome synapsis and abnormal centromere cohesion in poly (ADP-Ribose) polymerase (Parp-1) null oocytes. Dev Biol. 2009;331:326. https:\/\/doi.org\/10.1016\/J.YDBIO.2009.05.550.","journal-title":"Dev Biol"},{"key":"1396_CR115","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1093\/HUMREP\/DEAA128","volume":"35","author":"AL Winship","year":"2020","unstructured":"Winship AL, Griffiths M, Requesens CL, Sarma U, Phillips KA, Hutt KJ. The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation. Hum Reprod. 2020;35:1864\u201374. https:\/\/doi.org\/10.1093\/HUMREP\/DEAA128.","journal-title":"Hum Reprod"},{"key":"1396_CR116","doi-asserted-by":"publisher","DOI":"10.1038\/S41598-020-74087-9","author":"K Nakamura","year":"2020","unstructured":"Nakamura K, Takae S, Shiraishi E, Shinya K, Igualada AJ, Suzuki N. Poly (ADP-Ribose) Polymerase inhibitor exposure reduces ovarian reserve followed by dysfunction in granulosa cells. Sci Rep. 2020. https:\/\/doi.org\/10.1038\/S41598-020-74087-9.","journal-title":"Sci Rep"},{"key":"1396_CR117","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.bbrc.2016.12.070","volume":"483","author":"DH Kim","year":"2017","unstructured":"Kim DH, Lee HR, Kim MG, Lee JS, Jin SJ, Lee HT. The effect of poly(ADP-ribosyl)ation inhibition on the porcine cumulus-oocyte complex during in vitro maturation. Biochem Biophys Res Commun. 2017;483:752\u20138. https:\/\/doi.org\/10.1016\/j.bbrc.2016.12.070.","journal-title":"Biochem Biophys Res Commun"},{"key":"1396_CR118","doi-asserted-by":"publisher","unstructured":"Titus S, Li F, Stobezki R, Akula K, Unsal E, Jeong K, Dickler M, Robson M, Moy F, Goswami S et al. Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. Sci Transl Med. 2013;5. https:\/\/doi.org\/10.1126\/SCITRANSLMED.3004925.","DOI":"10.1126\/SCITRANSLMED.3004925"},{"key":"1396_CR119","doi-asserted-by":"publisher","DOI":"10.1111\/CAS.16412","volume":"116","author":"S Kaseki","year":"2025","unstructured":"Kaseki S, Sonehara R, Motooka Y, Tanaka H, Nakamura T, Osuka S, et al. Susceptibility of Brca1 (L63X\/+) rat to ovarian reserve dissipation by chemotherapeutic agents to breast cancer. Cancer Sci. 2025;116:1139. https:\/\/doi.org\/10.1111\/CAS.16412.","journal-title":"Cancer Sci"},{"key":"1396_CR120","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1530\/REP-13-0588","volume":"147","author":"A Joshi","year":"2014","unstructured":"Joshi A, Mahfooz S, Maurya VK, Kumar V, Basanna CS, Kaur G, et al. PARP1 during embryo implantation and its upregulation by oestradiol in mice. Reproduction. 2014;147:765\u201380. https:\/\/doi.org\/10.1530\/REP-13-0588.","journal-title":"Reproduction"},{"key":"1396_CR121","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2020.110946","author":"UK Soni","year":"2020","unstructured":"Soni UK, Chadchan SB, Joshi A, Kumar V, Maurya VK, Verma RK, et al. Poly(ADP-Ribose) Polymerase-2 is essential for endometrial receptivity and blastocyst implantation, and regulated by caspase-8. Mol Cell Endocrinol. 2020. https:\/\/doi.org\/10.1016\/j.mce.2020.110946.","journal-title":"Mol Cell Endocrinol"},{"key":"1396_CR122","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1093\/EMBOJ\/CDG206","volume":"22","author":"J M\u00e9nissier de Murcia","year":"2003","unstructured":"M\u00e9nissier de Murcia J, Ricoul M, Tartier L, Niedergang C, Huber A, Dantzer F, et al. Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse. EMBO J. 2003;22:2255\u201363. https:\/\/doi.org\/10.1093\/EMBOJ\/CDG206.","journal-title":"EMBO J"},{"key":"1396_CR123","doi-asserted-by":"publisher","DOI":"10.1073\/PNAS.2109252118","author":"AM Kelleher","year":"2021","unstructured":"Kelleher AM, Setlem R, Dantzer F, DeMayo FJ, Lydon JP, Kraus LW. Deficiency of PARP-1 and PARP-2 in the mouse uterus results in decidualization failure and pregnancy loss. Proc Natl Acad Sci U S A. 2021. https:\/\/doi.org\/10.1073\/PNAS.2109252118.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1396_CR124","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1200\/JCO.20.02880","volume":"39","author":"V Turan","year":"2021","unstructured":"Turan V, Lambertini M, Lee DY, Wang E, Clatot F, Karlan BY, et al. Association of germline BRCA pathogenic variants with diminished ovarian reserve: a meta-analysis of individual patient-level data. J Clin Oncol. 2021;39:2016\u201324. https:\/\/doi.org\/10.1200\/JCO.20.02880.","journal-title":"J Clin Oncol"},{"key":"1396_CR125","doi-asserted-by":"publisher","DOI":"10.3389\/FENDO.2019.00235","author":"KA Son","year":"2019","unstructured":"Son KA, Lee DY, Choi DS. Association of BRCA mutations and anti-m\u00fcllerian hormone level in young breast cancer patients. Front Endocrinol (Lausanne). 2019. https:\/\/doi.org\/10.3389\/FENDO.2019.00235.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1396_CR126","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1200\/JCO.2009.24.2057","volume":"28","author":"K Oktay","year":"2010","unstructured":"Oktay K, Kim JY, Barad D, Babayev SN. Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast\/ovarian cancer risks. J Clin Oncol. 2010;28:240\u20134. https:\/\/doi.org\/10.1200\/JCO.2009.24.2057.","journal-title":"J Clin Oncol"},{"key":"1396_CR127","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/annonc\/mdx639","volume":"29","author":"M Lambertini","year":"2018","unstructured":"Lambertini M, Goldrat O, Ferreira AR, Dechene J, Azim HA, Desir J, et al. Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients. Ann Oncol. 2018;29:237\u201343. https:\/\/doi.org\/10.1093\/annonc\/mdx639.","journal-title":"Ann Oncol"},{"key":"1396_CR128","doi-asserted-by":"publisher","first-page":"3839","DOI":"10.1210\/JC.2017-00765","volume":"102","author":"W Lin","year":"2017","unstructured":"Lin W, Titus S, Moy F, Ginsburg ES, Oktay K. Ovarian aging in women with BRCA germline mutations. J Clin Endocrinol Metab. 2017;102:3839\u201347. https:\/\/doi.org\/10.1210\/JC.2017-00765.","journal-title":"J Clin Endocrinol Metab"},{"key":"1396_CR129","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1002\/CNCR.27952","volume":"119","author":"WT Lin","year":"2013","unstructured":"Lin WT, Beattie M, Chen LM, Oktay K, Crawford SL, Gold EB, et al. Comparison of age at natural menopause in BRCA1\/2 mutation carriers with a non-clinic-based sample of women in Northern California. Cancer. 2013;119:1652\u20139. https:\/\/doi.org\/10.1002\/CNCR.27952.","journal-title":"Cancer"},{"key":"1396_CR130","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/S10549-006-9220-1","volume":"100","author":"I Rzepka-G\u00f3rska","year":"2006","unstructured":"Rzepka-G\u00f3rska I, Tarnowski B, Chudecka-G\u0142az A, G\u00f3rski B, Zieli\u0144ska D, To\u0142oczko-Grabarek A. Premature menopause in patients with BRCA1 gene mutation. Breast Cancer Res Treat. 2006;100:59\u201363. https:\/\/doi.org\/10.1007\/S10549-006-9220-1.","journal-title":"Breast Cancer Res Treat"},{"key":"1396_CR131","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.fertnstert.2020.01.033","volume":"113","author":"KH Oktay","year":"2020","unstructured":"Oktay KH, Bedoschi G, Goldfarb SB, Taylan E, Titus S, Palomaki GE, et al. Increased chemotherapy-induced ovarian reserve loss in women with germline BRCA mutations due to oocyte deoxyribonucleic acid double strand break repair deficiency. Fertil Steril. 2020;113:1251-1260.e1. https:\/\/doi.org\/10.1016\/j.fertnstert.2020.01.033.","journal-title":"Fertil Steril"},{"key":"1396_CR132","doi-asserted-by":"publisher","DOI":"10.1177\/11782234241261429","author":"IM Magaton","year":"2024","unstructured":"Magaton IM, Arecco L, Mariamidze E, Jankovic K, Stana M, Buzzatti G, et al. Fertility and pregnancy-related issues in young BRCA carriers with breast cancer. Breast Cancer (Auckl). 2024. https:\/\/doi.org\/10.1177\/11782234241261429.","journal-title":"Breast Cancer (Auckl)"},{"key":"1396_CR133","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100300","volume":"6","author":"M Condorelli","year":"2021","unstructured":"Condorelli M, Bruzzone M, Ceppi M, Ferrari A, Grinshpun A, Hamy AS, et al. Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1\/2 with a pregnancy after prior history of breast cancer. ESMO Open. 2021;6:100300. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100300.","journal-title":"ESMO Open"},{"key":"1396_CR134","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1159\/000546095","volume":"18","author":"R Omori","year":"2025","unstructured":"Omori R, Gonda K, Arai M, Sawano T, Kurokawa T, Tamada Y, et al. Unexpected twin pregnancy in a BRCA2-Positive breast cancer patient with post-chemotherapy amenorrhea: a case report and call for comprehensive contraceptive counseling. Case Rep Oncol. 2025;18:721\u20137. https:\/\/doi.org\/10.1159\/000546095.","journal-title":"Case Rep Oncol"},{"issue":"2","key":"1396_CR135","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s12276-025-01395-3","volume":"57","author":"A Shanabag","year":"2025","unstructured":"Shanabag A, Armand J, Son E, Yang HW. Targeting CDK4\/6 in breast cancer. Exp Mol Med. 2025;57(2):312\u201322. https:\/\/doi.org\/10.1038\/s12276-025-01395-3.","journal-title":"Exp Mol Med"},{"key":"1396_CR136","doi-asserted-by":"publisher","DOI":"10.3389\/FPHAR.2025.1564437\/BIBTEX","volume":"16","author":"Y Liu","year":"2025","unstructured":"Liu Y, Su J, Wu P, Lv W. Long-term efficacy of CDK4\/6 inhibitors in early HR+, HER2- high-risk breast cancer: an updated systematic review and meta-analysis. Front Pharmacol. 2025;16:1564437. https:\/\/doi.org\/10.3389\/FPHAR.2025.1564437\/BIBTEX.","journal-title":"Front Pharmacol"},{"key":"1396_CR137","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1200\/JCO.21.02742","volume":"40","author":"M Royce","year":"2022","unstructured":"Royce M, Osgood C, Mulkey F, Bloomquist E, Pierce WF, Roy A, et al. FDA approval summary: Abemaciclib with endocrine therapy for high-risk early breast cancer. J Clin Oncol. 2022;40:1155\u201362. https:\/\/doi.org\/10.1200\/JCO.21.02742.","journal-title":"J Clin Oncol"},{"key":"1396_CR138","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","volume":"24","author":"SRD Johnston","year":"2023","unstructured":"Johnston SRD, Toi M, O\u2019Shaughnessy J, Rastogi P, Campone M, Neven P, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-Negative, node-positive, high-risk early breast cancer (MonarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24:77\u201390. https:\/\/doi.org\/10.1016\/S1470-2045(22)00694-5.","journal-title":"Lancet Oncol"},{"key":"1396_CR139","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1200\/JCO.23.01994","volume":"42","author":"P Rastogi","year":"2024","unstructured":"Rastogi P, O\u2019shaughnessy J, Martin M, Boyle F, Cortes J, Rugo HS, et al. Adjuvant Abemaciclib plus endocrine therapy for hormone receptor\u2013positive, Human Epidermal Growth Factor Receptor 2\u2013Negative, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes. J Clin Oncol. 2024;42:987\u201393. https:\/\/doi.org\/10.1200\/JCO.23.01994.","journal-title":"J Clin Oncol"},{"key":"1396_CR140","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMOA2305488","volume":"390","author":"D Slamon","year":"2024","unstructured":"Slamon D, Lipatov O, Nowecki Z, McAndrew N, Kukielka-Budny B, Stroyakovskiy D, et al. Ribociclib plus endocrine therapy in early breast cancer. N Engl J Med. 2024;390:1080\u201391. https:\/\/doi.org\/10.1056\/NEJMOA2305488.","journal-title":"N Engl J Med"},{"key":"1396_CR141","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/S12276-025-01395-3","volume":"57","author":"A Shanabag","year":"2025","unstructured":"Shanabag A, Armand J, Son E, Yang HW. Targeting CDK4\/6 in breast cancer. Exp Mol Med. 2025;57:312\u201322. https:\/\/doi.org\/10.1038\/S12276-025-01395-3.","journal-title":"Exp Mol Med"},{"key":"1396_CR142","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1095\/BIOLREPROD.103.017335","volume":"70","author":"J Kohoutek","year":"2004","unstructured":"Kohoutek J, Dvo\u0159\u00e1k P, Hampl A. Temporal distribution of CDK4, CDK6, D-type cyclins, and P27 in developing mouse oocytes. Biol Reprod. 2004;70:139\u201345. https:\/\/doi.org\/10.1095\/BIOLREPROD.103.017335.","journal-title":"Biol Reprod"},{"key":"1396_CR143","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS15204923","author":"G Scavone","year":"2023","unstructured":"Scavone G, Ottonello S, Blondeaux E, Arecco L, Scaruffi P, Stigliani S, et al. The role of Cyclin-dependent kinases (CDK) 4\/6 in the ovarian tissue and the possible effects of their exogenous inhibition. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/CANCERS15204923.","journal-title":"Cancers (Basel)"},{"key":"1396_CR144","doi-asserted-by":"publisher","first-page":"7011","DOI":"10.1128\/MCB.19.10.7011","volume":"19","author":"T Tsutsui","year":"1999","unstructured":"Tsutsui T, Hesabi B, Moons DS, Pandolfi PP, Hansel KS, Koff A, et al. Targeted disruption of CDK4 delays cell cycle entry with enhanced P27(Kip1) activity. Mol Cell Biol. 1999;19:7011\u20139. https:\/\/doi.org\/10.1128\/MCB.19.10.7011.","journal-title":"Mol Cell Biol"},{"key":"1396_CR145","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.cell.2004.08.002","volume":"118","author":"M Malumbres","year":"2004","unstructured":"Malumbres M, Sotillo R, Santamar\u00eda D, Gal\u00e1n J, Cerezo A, Ortega S, et al. Mammalian cells cycle without the d-type cyclin-dependent kinases Cdk4 and Cdk6. Cell. 2004;118:493\u2013504. https:\/\/doi.org\/10.1016\/j.cell.2004.08.002.","journal-title":"Cell"},{"key":"1396_CR146","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1080\/10520295.2024.2389524","volume":"99","author":"Z Huyut","year":"2024","unstructured":"Huyut Z, U\u00e7ar B, Y\u0131ld\u0131zhan K, Alt\u0131nda\u011f F, Huyut MT. Effect of Abemaciclib and Curcumin administration on sex hormones, reproductive functions, and oxidative DNA expression in rats. Biotech Histochem. 2024;99:339\u201347. https:\/\/doi.org\/10.1080\/10520295.2024.2389524.","journal-title":"Biotech Histochem"},{"key":"1396_CR147","doi-asserted-by":"publisher","DOI":"10.15252\/EMBJ.2021108599","author":"L Crozier","year":"2022","unstructured":"Crozier L, Foy R, Mouery BL, Whitaker RH, Corno A, Spanos C, et al. CDK4\/6 inhibitors induce replication stress to cause long-term cell cycle withdrawal. EMBO J. 2022. https:\/\/doi.org\/10.15252\/EMBJ.2021108599.","journal-title":"EMBO J"},{"key":"1396_CR148","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1002\/MRD.23241","volume":"86","author":"Y Li","year":"2019","unstructured":"Li Y, Zhang L, Shan Y, Jia C, Xu Y. CDK4\/6 inhibitor protects Chemerin-induced human granulosa-lutein cells from apoptosis by inhibiting the P53\/P21 Waf pathway. Mol Reprod Dev. 2019;86:1561\u20138. https:\/\/doi.org\/10.1002\/MRD.23241.","journal-title":"Mol Reprod Dev"},{"key":"1396_CR149","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103466","author":"F Marm\u00e9","year":"2024","unstructured":"Marm\u00e9 F, Martin M, Untch M, Thode C, Bonnefoi H, Kim SB, et al. Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B. ESMO Open. 2024. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103466.","journal-title":"ESMO Open"},{"key":"1396_CR150","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.reprotox.2019.07.016","volume":"88","author":"NR Catlin","year":"2019","unstructured":"Catlin NR, Bowman CJ, Engel SM, Sacaan A, Thibault S, Lewis EM, et al. Reproductive and developmental toxicity assessment of Palbociclib, a CDK4\/6 inhibitor, in Sprague-Dawley rats and New Zealand White rabbits. Reprod Toxicol. 2019;88:76\u201384. https:\/\/doi.org\/10.1016\/j.reprotox.2019.07.016.","journal-title":"Reprod Toxicol"},{"key":"1396_CR151","doi-asserted-by":"publisher","DOI":"10.1002\/PRP2.599","author":"AD James","year":"2020","unstructured":"James AD, Schiller H, Marvalin C, Jin Y, Borell H, Roffel AF, et al. An integrated assessment of the ADME properties of the CDK4\/6 inhibitor ribociclib utilizing preclinical in vitro, in vivo, and human ADME data. Pharmacol Res Perspect. 2020. https:\/\/doi.org\/10.1002\/PRP2.599.","journal-title":"Pharmacol Res Perspect"},{"key":"1396_CR152","unstructured":"U.S. Food and Drug Administration. Multi-disciplinary review and evaluation:ribociclib. NDA 209092. Silver Spring, MD: U.S. Food and Drug Administration. 2017. https:\/\/accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/209092rig1s000MultidisciplineR.pdf"},{"key":"1396_CR153","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.3390\/BIOENGINEERING12111171\/S1","volume":"12","author":"L Song","year":"2025","unstructured":"Song L, Edib Z, Aickelin U, Akbarzadeh Khorshidi H, Hamy AS, Jayasinghe Y, et al. Development of a machine learning model for predicting treatment-related amenorrhea in young women with breast cancer. Bioengineering. 2025;12:1171. https:\/\/doi.org\/10.3390\/BIOENGINEERING12111171\/S1.","journal-title":"Bioengineering"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-026-01396-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-026-01396-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-026-01396-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T03:43:58Z","timestamp":1780026238000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-026-01396-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":153,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1396"],"URL":"https:\/\/doi.org\/10.1007\/s11864-026-01396-y","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"2 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"30"}}